Cefodizime: the Japanese Clinical Experience

Overview

Journal Infection

Date 1992 Jan 1

PMID 1526674

Authors

K Matsumoto

Affiliations

Soon will be listed here.

Abstract

In a clinical trial conducted in Japan from 1985-1988, the efficacy of cefodizime was studied in 2,227 adult and 449 pediatric patients. Of these, 1,366 adult and 203 pediatric patients had pathogens isolated and were evaluable. Cefodizime was effective in 78.8% of the adult patients, and adverse reactions occurred in 2.3%. In pediatric patients cefodizime was effective in 91.1% of the cases, and adverse reactions developed in 5.1%. A very high concentration of cefodizime is achieved in blood soon after administration and its penetration into tissues is also high. Moreover, cefodizime exhibits phagocytosis enhancement activity. The above-mentioned excellent efficacy rates, low rates of side effects and enhancement of phagocytic activity make cefodizime an antibiotic of choice in adult and pediatric patients.

References

Oishi K, Matsumoto K, Yamamoto M, Morito T, Yoshida T . Stimulatory effect of cefodizime on macrophage-mediated phagocytosis. J Antibiot (Tokyo). 1989; 42(6):989-92. DOI: 10.7164/antibiotics.42.989. View

Limbert M, Bartlett R, Dickneite G, Klesel N, Schorlemmer H, Seibert G . Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo). 1984; 37(12):1719-26. DOI: 10.7164/antibiotics.37.1719. View

Jones R, Barry A, Thornsberry C, Wilson H . In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Antimicrob Agents Chemother. 1981; 20(6):760-8. PMC: 181795. DOI: 10.1128/AAC.20.6.760. View

Ohnishi H, Kosuzume H, Inaba H, Okura M, Mochizuki H, Suzuki Y . Effects of AC-1370, a new semisynthetic cephalosporin, on phagocyte functions. Antimicrob Agents Chemother. 1983; 23(6):874-80. PMC: 184990. DOI: 10.1128/AAC.23.6.874. View